A Cross-Sectional Study Comparing Mir-503-5p Expression in Gastric Cancer Patients Before and After Chemotherapy

1. Thrumurthy SG, Chaudry MA,
Hochhauser D, Mughal M. The
diagnosis and management of gastric
cancer. Bmj. 2013;347.
2. Karimi P, Islami F, Anandasabapathy
S, Freedman ND, Kamangar F. Gastric
cancer: descriptive epidemiology, risk
factors, screening, and prevention.
Cancer epidemiology, biomarkers &
prevention. 2014;23(5):700-13.
3. Clinton SK, Giovannucci EL, Hursting
SD. The world cancer research fund/
American institute for cancer research
third expert report on diet, nutrition,
physical activity, and cancer: impact
and future directions. The Journal of
nutrition. 2020;150(4):663-71.
4. Lauren P. Diffuse and so-called
intestinal type carcinoma: an
attempt at histological classification.
Acta Pathol Microbiol Scand.
1965;64:31-49.
5. Bray F, Laversanne M, Sung H,
Ferlay J, Siegel RL, Soerjomataram
I, et al. Global cancer statistics
2022: GLOBOCAN estimates of
incidence and mortality worldwide
for 36 cancers in 185 countries.
CA: a cancer journal for clinicians.
2024;74(3):229-63.
6. Chiba T, Marusawa H, Seno H,
Watanabe N. Mechanism for gastric
cancer development by Helicobacter
pylori infection. Journal of
gastroenterology and hepatology.
2008;23(8pt1):1175-81.
7. Guo Y, Zhang Y, Gerhard M, Gao
J-J, Mejias-Luque R, Zhang L, et
al. Effect of Helicobacter pylori
on gastrointestinal microbiota: a
population-based study in Linqu, a
high-risk area of gastric cancer. Gut.
2020;69(9):1598-607.
8. Ferlay J, Ervik M, Lam F, Colombet
M, Mery L, Piñeros M, et al. Global
cancer observatory: cancer today.
Lyon, France: international agency
for research on cancer. 2018.
9. van Der Kaaij RT, Koemans WJ,
van Putten M, Snaebjornsson P,
Luijten JC, van Dieren JM, et al. A
population-based study on intestinal
and diffuse type adenocarcinoma
of the oesophagus and stomach in
the Netherlands between 1989 and
2015. European Journal of Cancer.
2020;130:23-31.
10. Kim Y, Jun JK, Choi KS, Lee H-Y,
Park E-C. Overview of the National
Cancer screening programme and
the cancer screening status in Korea.
2011.
11. Hamashima C, Group SR, Guidelines
GDGfGCS. Update version of the
Japanese guidelines for gastric cancer
screening. Japanese journal of clinical
oncology. 2018;48(7):673-83.
12. Facciorusso A, Antonino M, Di
Maso M, Muscatiello N. Endoscopic
submucosal dissection vs endoscopic
mucosal resection for early gastric
cancer: A meta-analysis. World
journal of gastrointestinal endoscopy.
2014;6(11):555.
13. Son T, Hyung WJ. Laparoscopic
gastric cancer surgery: current
evidence and future perspectives.
World Journal of Gastroenterology.
2016;22(2):727.
14. Machlowska J, Baj J, Sitarz M,
Maciejewski R, Sitarz R. Gastric
cancer: epidemiology, risk factors,
classification, genomic characteristics
and treatment strategies. International
journal of molecular sciences.
2020;21(11):4012.
15. Xu D-z, Geng Q-r, Tian Y, Cai M-y,
Fang X-j, Zhan Y-q, et al. Activated
mammalian target of rapamycin is a
potential therapeutic target in gastric
cancer. BMC cancer. 2010;10:1-10.
16. Ambros V. The functions of
animal microRNAs. Nature.
2004;431(7006):350-5.
17. Reda El Sayed S, Cristante J, Guyon
L, Denis J, Chabre O, Cherradi N.
MicroRNA therapeutics in cancer:
current advances and challenges.
Cancers. 2021;13(11):2680.
18. Calin GA, Dumitru CD, Shimizu
M, Bichi R, Zupo S, Noch E, et
al. Frequent deletions and down-
regulation of micro-RNA genes
miR15 and miR16 at 13q14 in chronic
lymphocytic leukemia. Proceedings
of the national academy of sciences.
2002;99(24):15524-9.
19. Hanahan D, Weinberg RA. Hallmarks
of cancer: the next generation. cell.
2011;144(5):646-74.
20. Lin S, Gregory RI. MicroRNA
biogenesis pathways in cancer. Nature
reviews cancer. 2015;15(6):321-33.
21. Hata A, Kashima R. Dysregulation
of microRNA biogenesis machinery
in cancer. Critical reviews in
biochemistry and molecular biology.
2016;51(3):121-34.
22. Cholewinski G, Waluga M. The role of
microRNAs in carcinogenesis and the
utility of microRNA determination
in diagnosis of gastric cancer
development. J Physiol Pharmacol.
2022;73(6).
23. Rupaimoole R, Calin GA, Lopez-
Berestein G, Sood AK. miRNA
deregulation in cancer cells and the
tumor microenvironment. Cancer
discovery. 2016;6(3):235-46.
24. Li W, Li J, Mu H, Guo M, Deng H.
MiR-503 suppresses cell proliferation
and invasion of gastric cancer by
targeting HMGA2 and inactivating
WNT signaling pathway. Cancer Cell
International. 2019;19:1-12.
25. Tan B, Li Y, Di Y, Fan L, Zhao
Q, Liu Q, et al. Clinical value of
peripheral blood microRNA detection
in evaluation of SOX regimen as
neoadjuvant chemotherapy for gastric
cancer. Journal of clinical laboratory
analysis. 2018;32(4):e22363.
26. Livak KJ, Schmittgen TD. Analysis
of relative gene expression data
using real-time quantitative PCR
and the 2− ΔΔCT method. methods.
2001;25(4):402-8.
27. Peng Y, Liu YM, Li LC, Wang LL,
Wu XL. microRNA-503 inhibits
gastric cancer cell growth and
epithelial-to-mesenchymal transition.
Oncology letters. 2014;7(4):1233-8.
28. Wu D, Cao G, Huang Z, Jin K, Hu
H, Yu J, et al. Decreased miR-503
expression in gastric cancer is
inversely correlated with serum
carcinoembryonic antigen and acts as
a potential prognostic and diagnostic
biomarker. OncoTargets and therapy.
2016:129-35.